Contact us to add description.
Finch Therapeutics is establishing a portfolio of microbiome therapeutics to treat patients with serious and unmet conditions. The microbiome consists of trillions of microbes that live symbiotically on and within humans. Disruption of the microbe composition can increase susceptibility to immune disorders, infections, neurological conditions and cancer. Finch is designing microbiome assets using insights from human microbiota transplantation studies that spans dozens of different conditions. With this information, Finch has established an extensive, multi-layered patent protection for multiple microbiome product strategies including donor-derived and donor-independent which they can now use to generate therapies.